国产人成无码视频在线观看,亚洲VA中文字幕无码久久不卡,东京热高清无码系列,北条麻妃在线一区二区

Cure Genetics announced the interim data of CAR-NK...
2024.05.20
Cure Genetics announced the interim data of CAR-NK...
This marked the first human trial using CAR-NKT therapy for RCC, demonstrating its good safety profile and anti-tumor activity.

More

>
Cure Genetics Awarded Third Place in the 2024 Biom...
2024.05.10
Cure Genetics Awarded Third Place in the 2024 Biom...
Cure Genetics distinguished itself from nearly a hundred international projects and was awarded third place in the 2024 Biomedical Pitch Competition

More

>
 Cure Genetics to Unveil Groundbreaking Achievemen...
2024.05.10
Cure Genetics to Unveil Groundbreaking Achievemen...
Cure Genetics will present for the first time the latest advancements of the CAR-NKT product CGC729 for RCC treatment through an oral presentation at the 2024 ASGCT Annual Meeting, and will also showcase four research findings related to the development of AAV serotypes.

More

>
A novel PD-1-IL-2v bispecific molecule for cancer ...
2024.05.10
A novel PD-1-IL-2v bispecific molecule for cancer ...
The journal Frontiers in Immunology recently reported on Cure Genetics' developed CGC-602 bispecific antibody molecule, which targets both PD-1 and IL-2. The IL-2v component is a variant derived from wild-type IL-2.

More

>
Dr. Pengcheng Zhou Joins Cure Genetics as Vice Pre...
2023.10.10
Dr. Pengcheng Zhou Joins Cure Genetics as Vice Pre...
Cure Genetics is delighted to announce that Dr. Pengcheng Zhou has joined the company on August 21, 2023, taking on the role of Vice President of Gene Therapy Research and Development, responsible for the research and translation of the company's gene therapy products. Dr. Zhou brings with him decades of extensive experience in the AAV gene therapy domain, showcasing remarkable achievements at leading academic institutions and renowned companies including Harvard University, Voyager, Luye Pharma, and Frontera Therapeutics.

More

>